Answers are grounded in this paper and cite their sources.
Background: Invasive lobular carcinoma (ILC) is a distinct breast cancer subtype with a characteristic infiltrative growth pattern linked to loss of E-cadherin. GI metastases may clinically and histologically mimic primary GI malignancies, creating significant diagnostic pitfalls. Case presentation: metastatic, grade 1, luminal A ILC (ER+/PR+, HER2 0; Ki-67 5%) diagnosed in 2022 achieved durable disease control with systemic therapy and maintenance ribociclib plus ovarian suppression. In late 2025, she developed progressive epigastric discomfort and rising tumour markers. Gastroduodenal endoscopy demonstrated erythematous gastric mucosa with focal whitish areas. Biopsies showed diffuse-type adenocarcinoma with signet ring morphology, initially interpreted as primary gastric cancer. Expert review with comparative pathology and extended immunohistochemistry demonstrated GATA3 and TRPS1 positivity, strong ER/PR expression, CDX2 negativity, and loss of E-cadherin, supporting gastric metastasis from ILC. Despite no clear radiologic progression on CT, symptomatic gastric involvement and weight loss prompted initiation of second-line weekly paclitaxel. Conclusion: Signet ring morphology in gastric biopsies is not pathognomonic for primary gastric carcinoma. In patients with current or prior ILC, an IHC panel incorporating breast-lineage markers (e.g., GATA3, TRPS1) and GI markers (e.g., CDX2, CK20), alongside E-cadherin status, is pivotal to avoid misdiagnosis, inappropriate surgery, and delay of systemic therapy.
No takes yet. Share an insight, caveat, or question.
Sofianidi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: